On Friday, Cullinan Therapeutics Inc (NASDAQ: CGEM) was 8.60% up from the session before settling in for the closing price of $8.72. A 52-week range for CGEM has been $5.68 – $13.78.
Annual sales at Healthcare sector company slipped by -45.66% over the past five years. When this article was written, the company’s average yearly earnings per share was at -30.30%. With a float of $39.43 million, this company’s outstanding shares have now reached $59.08 million.
Cullinan Therapeutics Inc (CGEM) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cullinan Therapeutics Inc stocks. The insider ownership of Cullinan Therapeutics Inc is 33.26%, while institutional ownership is 77.35%. The most recent insider transaction that took place on Oct 28 ’25, was worth 1,391,686. In this transaction 10% Owner of this company bought 165,667 shares at a rate of $8.40, taking the stock ownership to the 8,963,500 shares. Before that another transaction happened on Oct 16 ’25, when Company’s 10% Owner bought 150,000 for $8.86, making the entire transaction worth $1,328,250. This insider now owns 8,765,616 shares in total.
Cullinan Therapeutics Inc (CGEM) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.73 earnings per share (EPS) during the time that was better than consensus figure (set at -0.74) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.9 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -30.30% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.59% during the next five years compared to -45.66% drop over the previous five years of trading.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Trading Performance Indicators
You can see what Cullinan Therapeutics Inc (CGEM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 10.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.68, a number that is poised to hit -0.82 in the next quarter and is forecasted to reach -3.11 in one year’s time.
Technical Analysis of Cullinan Therapeutics Inc (CGEM)
Cullinan Therapeutics Inc (NASDAQ: CGEM) saw its 5-day average volume 1.12 million, a positive change from its year-to-date volume of 0.58 million. As of the previous 9 days, the stock’s Stochastic %D was 74.59%.
During the past 100 days, Cullinan Therapeutics Inc’s (CGEM) raw stochastic average was set at 87.13%, which indicates a significant increase from 83.02% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.67 in the past 14 days, which was higher than the 0.48 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.34, while its 200-day Moving Average is $7.89. Nevertheless, the first resistance level for the watch stands at $10.16 in the near term. At $10.85, the stock is likely to face the second major resistance level. The third major resistance level sits at $11.67. If the price goes on to break the first support level at $8.65, it is likely to go to the next support level at $7.83. Assuming the price breaks the second support level, the third support level stands at $7.14.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Key Stats
There are 59,076K outstanding shares of the company, which has a market capitalization of 559.45 million. As of now, sales total 0 K while income totals -167,380 K. Its latest quarter income was 0 K while its last quarter net income were -50,610 K.
